Amarin Co. plc (NASDAQ:AMRN) was the recipient of a significant increase in short interest in the month of May. As of May 30th, there was short interest totalling 28,752,172 shares, an increase of 8.1% from the May 15th total of 26,592,026 shares, AnalystRatings.Net reports. Approximately 17.4% of the company’s shares are short sold. Based on an average daily volume of 1,497,932 shares, the days-to-cover ratio is currently 19.2 days.
AMRN has been the subject of a number of recent research reports. Analysts at MKM Partners reiterated a “fair value” rating on shares of Amarin Co. plc in a research note on Monday, May 12th. They now have a $1.50 price target on the stock, down previously from $2.00. Separately, analysts at Aegis reiterated a “hold” rating on shares of Amarin Co. plc in a research note on Monday, May 12th. Finally, analysts at Citigroup Inc. downgraded shares of Amarin Co. plc from a “buy” rating to a “neutral” rating in a research note on Friday, May 9th. Eleven analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $4.18.
Amarin Co. plc (NASDAQ:AMRN) opened at 1.53 on Friday. Amarin Co. plc has a 1-year low of $1.28 and a 1-year high of $7.40. The stock’s 50-day moving average is $1.49 and its 200-day moving average is $1.73. The company’s market cap is $264.5 million.
Amarin Co. plc (NASDAQ:AMRN) last announced its earnings results on Friday, May 9th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.18) by $0.02. The company had revenue of $11.00 million for the quarter, compared to the consensus estimate of $11.65 million. The company’s quarterly revenue was up 378.3% on a year-over-year basis. On average, analysts predict that Amarin Co. plc will post $-0.55 earnings per share for the current fiscal year.
Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.